Company: BNBX
Filing Date: 2025-11-04
Form Type: 8-K
Source: 0001104659-25-105945
Chunk: 0

Company: BNB PLUS CORP.
Filing Date: 2025-11-04
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement  

On
November 4, 2025, Applied DNA Sciences, Inc. (the “ Company”) entered into an At The Market Offering Agreement
(the “ Agreement”) with Lucid Capital Markets, LLC, as sales agent (the “ Agent”), pursuant to
which the Company may, from time to time, offer and sell shares of its common stock, par value $0.001 per share, with an aggregate
offering price of up to $8,157,932 (the “ Shares”) through the Agent.

The
offer and sale of the Shares made pursuant to the Agreement, if any, will be made under the Company’s effective
“shelf” registration statement on Form S-3 (File No. 333-272267) filed May 30, 2023, the base prospectus contained
therein, and a prospectus supplement related to the offering of the Shares dated November 4, 2025.

Under
the terms of the Agreement, the Agent may sell the Shares at market prices by any method that is deemed to be an “at the market
offering” as defined in Rule 415 under the Securities Act of 1933, as amended.

Subject
to the terms and conditions of the Agreement, the Agent will use its commercially reasonable efforts to sell the Shares from time to time,
based upon the Company’s instructions. The Company has no obligation to sell any of the Shares, and may at any time suspend sales
under the Agreement or terminate the Agreement in accordance with its terms. The Company has provided the Agent with customary indemnification
rights. The Agreement contains customary representations and warranties, and the Company is required to deliver customary closing documents
and certificates in connection with sales of the Shares.

The
Company will pay the Agent in cash, upon each sale of Shares sold pursuant to the Agreement, a fixed commission rate equal
to 3.0% of the gross sales price of the common stock issued and sold by the Company through the Agent. If the Company sells Shares to
the Agent as principal, the Company will enter into a separate terms agreement with the Agent setting forth the terms of such
transaction, and the Company will describe this agreement in a separate prospectus supplement or pricing supplement. Because there is
no minimum offering amount required as a condition to this offering, the actual total public offering amount, commissions and proceeds
to the Company, if any, are not determinable at this time.